Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate

Hosking, David, Lyles, Kenneth, Brown, Jacques P, Fraser, William D, Miller, Paul, Curiel, Manuel Diaz, Devogelaer, Jean-Pierre, Hooper, Michael, Su, Guoqin, Zelenakas, Ken, Pak, Judy, Fashola, Taiwo, Saidi, Youssef, Eriksen, Erik Fink and Reid, Ian R (2007) Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. Journal of Bone and Mineral Research, 22 (1). pp. 142-148. ISSN 1523-4681

Full text not available from this repository. (Request a copy)

Abstract

A single 5-mg infusion of zoledronic acid restores biochemical markers of bone turnover into the reference range in the majority of patients with Paget's disease and maintains biochemical remission for at least 2 years. This effect is largely independent of pretreatment disease activity and prior bisphosphonate therapy.

Item Type: Article
Uncontrolled Keywords: administration, oral,aged,aged, 80 and over,alkaline phosphatase,bone density conservation agents,bone and bones,diphosphonates,etidronic acid,follow-up studies,humans,imidazoles,infusions, intravenous,osteitis deformans
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
University of East Anglia > Faculty of Medicine and Health Sciences > Research Groups > Musculoskeletal Science
Faculty of Arts and Humanities > School of American Studies
Related URLs:
Depositing User: Rhiannon Harvey
Date Deposited: 08 Jun 2011 14:05
Last Modified: 25 Jul 2018 06:02
URI: https://ueaeprints.uea.ac.uk/id/eprint/32062
DOI: 10.1359/jbmr.061001

Actions (login required)

View Item